Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label multi facilities cooperation randomized control trial to verify renoprotective effects of improvement in postprandial hyperglycemia in diabetic nephropathy.

Next Previous
Trial Profile

An open label multi facilities cooperation randomized control trial to verify renoprotective effects of improvement in postprandial hyperglycemia in diabetic nephropathy.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mitiglinide (Primary) ; Glimepiride
  • Indications Diabetic nephropathies; Type 2 diabetes mellitus
  • Focus Therapeutic Use

Most Recent Events

  • 11 Jan 2019 Status changed from recruiting to completed.
  • 09 Nov 2011 Planned End Date changed from 1 Apr 2015 to 1 Sep 2015 as reported by University Hospital Medical Information Network - Japan.
  • 25 Jan 2011 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top